Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Tilray Stock Before the Aphria Merger?

By Keith Speights - Mar 3, 2021 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a few things to consider first.

The clock is ticking on the completion of the biggest marijuana merger ever. Aphria (APHA) and Tilray (TLRY) expect to close their planned merger in the second quarter of this year. 

Both cannabis stocks have been big winners so far in 2021 in anticipation of the combination of the two companies. Aphria's shares are up over 170%, while Tilray stock has more than tripled year to date. But should you buy Tilray before the Aphria merger?

Hands holding two green jigsaw puzzle pieces close to each other

Image source: Getty Images.

Why buy Tilray?

There's basically only one reason why investors should consider buying Tilray stock: They expect it to move higher. Is that a reasonable expectation after the huge gains already generated in recent months? Maybe.

It's not hard to identify things to like with the Aphria-Tilray merger. The companies' strengths in the Canadian cannabis market complement each other. Aphria brings a stronger financial position to the table, thanks in large part to its CC Pharma distribution business in Germany. The cannabis producers think that they'll be able to achieve synergies of around 100 million in Canadian dollars (roughly $79 million).

The "new" Tilray after the merger will claim the No. 1 market share in the Canadian retail cannabis market. It will be a major player in Europe, with Aphria's existing position in Germany and Tilray's Portugal operations. The company will also have a foothold in the U.S. with Aphria's acquisition of SweetWater Brewing and Tilray's Manitoba Harvest hemp foods business.

All of this could give the combined company tremendous momentum. Assuming that happens, buying Tilray now makes sense.

Taking the opposite move

However, if you're optimistic about how the merger of Aphria and Tilray positions the resulting company, there's an even smarter move to make. Instead of buying Tilray, buy Aphria.

While the company will be named Tilray following the close of the transaction, Aphria is clearly in the driver's seat. Current Aphria chairman and CEO Irwin Simon will serve in the same roles with the "new" Tilray. Aphria will hold seven of the nine board seats.

Most importantly, though, Aphria shareholders will receive 0.8381 shares of Tilray for each Aphria share they own. Tilray shareholders will keep their existing number of shares. This presents an arbitrage opportunity for investors.

Currently, Aphria's share price is around 0.73 times Tilray's share price. The completion of the merger will get that ratio to the agreed-upon 0.8381. This means that Aphria's share price either needs to go up, Tilray's share price needs to come down, or both. Buying Aphria shares and shorting Tilray is arguably the best play to profit from the upcoming merger.

My view

In my opinion, buying Tilray stock right now isn't a great idea. The arbitrage opportunity is one reason why. However, I think there's an even bigger reason.

Unlike playing baseball, investing in marijuana stocks doesn't require you to swing at pitches or face the risk of striking out. You can wait for the best pitch. With this analogy in mind, I think that there are simply better pitches to swing at than the Tilray curveball.

In particular, my view is that there are several U.S. cannabis stocks, in particular, that are more attractive than Tilray (and Aphria, for that matter). The clock might be ticking on the upcoming merger between Aphria and Tilray, but investors don't have to rush into buying either stock when others are even better.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
Aphria Stock Quote
Aphria
APHA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.